Pantazis P, Mendoza J T, DeJesus A, Rubin E, Kufe D, Giovanella B C
Stehlin Foundation for Cancer Research, St. Joseph Hospital, Houston, Texas 77003.
Eur J Haematol. 1994 Sep;53(3):135-44. doi: 10.1111/j.1600-0609.1994.tb00661.x.
Human leukemia U-937 cell sublines exhibiting various levels of resistance to 9-nitrocamptothecin (9NC) were developed after exposure to progressively increased 9NC concentrations. Increases in 9NC resistance of the cells were accompanied by decreases in proliferation rate; appearance of morphological and functional features that correlate with granulocytic maturation; decreased synthesis of topoisomerase I; increased synthesis of topoisomerase II; and inability or decreased ability to induce tumors when xenografted in nude mice. 9NC-resistant cells, transferred and propagated in 9NC-free media for 6 months, continue to exhibit resistance and other features similar to cells propagated in continual presence of 9NC. Finally, 9NC-resistant U-937 cells respond to physiological and non-physiological agents of cell differentiation, indicating that alternative treatments can be successfully used to inhibit growth of 9NC-resistant U-937 cells and tumors.
在暴露于逐步增加的9-硝基喜树碱(9NC)浓度后,培育出了对9-硝基喜树碱表现出不同耐药水平的人白血病U-937细胞亚系。细胞对9NC耐药性的增加伴随着增殖速率的降低;出现与粒细胞成熟相关的形态和功能特征;拓扑异构酶I合成减少;拓扑异构酶II合成增加;以及异种移植到裸鼠体内时诱导肿瘤的能力丧失或降低。对9NC耐药的细胞在无9NC的培养基中传代培养6个月后,仍继续表现出耐药性以及与在持续存在9NC的情况下传代培养的细胞相似的其他特征。最后,对9NC耐药的U-937细胞对细胞分化的生理和非生理因子有反应,这表明替代疗法可成功用于抑制对9NC耐药的U-937细胞和肿瘤的生长。